ALKS - Alkermes plc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
34%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -3.6%
Operating Income is Negative but improving
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -8.12%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.32
Debt Ratio is 0.45
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.15
Cash Flow is STRONG
Cash from Operations Growth is 139.78%
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alkermes plc (ALKS) - www.alkermes.com
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO -
Employees - 2,245
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.